Brief: Evaxion Reports 75% Objective Response Rate In Phase 2 Trial With Ai-Designed Personalized Cancer Vaccine EVX-01
17/10/2025 13:18
Oct 17 (Reuters) - Evaxion A/S EVAX.O: EVAXION REPORTS 75% OBJECTIVE RESPONSE RATE IN PHASE 2 TRIAL WITH AI-DESIGNED PERSONALIZED CANCER VACCINE EVX-01 EVAXION A/S - 75% OBJECTIVE RESPONSE RATE AS 12 OUT OF 16 ADVANCED MELANOMA PATIENTS HAD OBJECTIVE CLINICAL RESPONSES EVAXION A/S - IMMUNE ACTIVATION OBSERVED IN ALL PATIENTS WITH 81% OF EVX-01'S VACCINE TARGETS TRIGGERING A SPECIFIC RESPONSE EVAXION A/S: TREATMENT WAS WELL TOLERATED IN PHASE 2 TRIAL Source text: ID:nGNX47RTtC Further company coverage: EVAX.O
Recent news on Evaxion A/S
See all newsEvaxion A/S reports results for the quarter ended June 30 - Earnings Summary
Denmark's Evaxion Q2 net loss narrows on lower expenses
Brief: Evaxion Q2 Basic EPS USD -0.01
Evaxion A/S expected to post a loss of 31 cents a share - Earnings Preview
Brief: Evaxion A/S - Expands Pipeline Of Cancer Vaccine Programs With Evx-05 Against Brain Cancer Glioblastoma